Nanoparticles Targeted Drug Delivery System via Epidermal Growth Factor Receptor: a Review
Abstract
Overexpressing of epidermal growth factor receptor (EGFR) in specific organ implicates tumour aggression and proliferation. Therefore, EGFR becomes a primary consideration for targeted cancer therapy. Nanoparticle drug delivery system is a promising multifunctional technique to provide the targeted drug delivery system. This review was aimed to discuss the nanoparticles formulation for targeted drug delivery system via EGFR. The data were collected from published journals recorded in the Scopus database. Various types of nanoparticles were widely studied to provide an EGFR-targeted drug delivery system. The formulations using specific targeting mediators were conjugated on several technologies such as polymeric nanoparticles, nanometals, and miscellaneous nanoparticles. Most of nanoparticles formulation become an excellent delivery carrier for drugs or gene to site-specific targeted by in vitro and in vivo evaluations. EGFR-targeted drug delivery system could be a promising technique to provide high effectiveness of drugs in EGFR-positive cells cancers with lower side effects to non-tumour cells.
Keywords : Epidermal growth factor receptor, Cancer, Nanoparticle, targeted drug
References
Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. cell Biol.2, 127 (2001)
Kondo, I. & Shimizu, N. Mapping of the human gene for epidermal growth factor receptor (EGFR) on the p13→ q22 region of chromosome 7. Cytogenet. Genome Res.35, 9–14 (1983).
Suzuki, S. et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: an immunohistochemical and fluorescence in situ hybridization study. Cancer Interdiscip. Int. J. Am. Cancer Soc.103, 1265–1273 (2005).
Eberhard, A. et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumours: implications for antiangiogenic tumour therapies. Cancer Res.60, 1388–1393 (2000).
Cataldo, V. D., Gibbons, D. L., Pérez-Soler, R. & Quintás-Cardama, A. Treatment of non–small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med.364, 947–955 (2011).
Wang, J. et al. Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC. Int. J. cancer144, 2677– 2682 (2019).
Burley, T. A. et al. Affibody-based PET imaging to guide EGFR-targeted cancer therapy in head and neck squamous cell cancer models. J. Nucl. Med.60, 353–361 (2019).
Ye, M. et al. Oxidized Vitamin C (DHA) Overcomes Resistance to EGFR-targeted Therapy of Lung Cancer through Disturbing Energy Homeostasis. J. Cancer10, 757 (2019).
Weng, W., Leung, W., Pang, Y. J., Kuo, L. & Hsu, H. EPA significantly improves anti EGFR targeted therapy by regulating miR 378 expression in colorectal cancer. Oncol. Lett.16, 6188–6194 (2018).
Dietel, E., Brobeil, A., Tag, C., Gattenloehner, S. & Wimmer, M. Effectiveness of EGFR/ HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cells. Oncogenesis7, 64 (2018).
Baker, L. C. J. et al. Evaluating imaging biomarkers of acquired resistance to targeted EGFR therapy in xenograft models of human head and neck squamous cell carcinoma. Front. Oncol.8, 271 (2018).
Peng, H. et al. Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platformbased analysis. BMC Cancer18, 323 (2018).
Railkar, R. et al. Epidermal growth factor receptor (EGFR)-targeted photoimmunotherapy (PIT) for the treatment of EGFR-expressing bladder cancer. Mol. Cancer Ther.16, 2201–2214 (2017).
Hou, H. et al. Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine. Oncotarget8, 105072 (2017).
Gajadhar, A. S., Bogdanovic, E., Muñoz, D. M. & Guha, A. In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy. Mol. Cancer Res.10, 428–440 (2012).
Gottschalk, N., Kimmig, R., Lang, S., Singh, M. & Brandau, S. Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity. Int. J. Mol. Sci.13, 12000–12016 (2012).
Ninomiya, T. et al. Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non– Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. Clin. Lung Cancer20, 134–138 (2019).
Colzani, B. et al. Design of smart GE11-PLGA/ PEG-PLGA blend nanoparticulate platforms for parenteral administration of hydrophilic macromolecular drugs: synthesis, preparation and in vitro/ex vivo characterization. Int. J. Pharm.511, 1112–1123 (2016).
Song, L., Falzone, N. & Vallis, K. A. EGFcoated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer. Int. J. Radiat. Biol.92, 716–723 (2016).
Wang, A. Z., Langer, R. & Farokhzad, O. C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med.63, 185–198 (2012). [21] Singh, R. & Lillard Jr, J. W. Nanoparticlebased targeted drug delivery. Exp. Mol. Pathol.86, 215–223 (2009).
Rizvi, S. A. A. & Saleh, A. M. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm. J.26, 64–70 (2018).
Kamei, K. et al. Integrated heart/cancer on a chip to reproduce the side effects of anticancer drugs in vitro. RSC Adv.7, 36777– 36786 (2017).
Hopper-Borge, E. A. et al. Mechanisms of tumour resistance to EGFR-targeted therapies. Expert Opin. Ther. Targets13, 339–362 (2009).
Morgillo, F., Martinelli, E., Troiani, T., Tortora, G. & Ciardiello, F. Combination of anti-egfr drugs and other molecular targeted agents as anti-cancer strategy. Curr. Cancer Ther. Rev.3, 117–126 (2007).
Morgillo, F., Bareschino, M. A., Bianco, R., Tortora, G. & Ciardiello, F. Primary and acquired resistance to anti EGFR targeted drugs in cancer therapy. Differentiation75, 788–799 (2007).
Cuneo, K. C., Nyati, M. K., Ray, D. & Lawrence, T. S. EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. Pharmacol. Ther.154, 67–77 (2015).
Skroński, M., Szpechciński, A. & Chorostowska-Wynimko, J. Current methods to detect EGFR gene mutations as predictive factor for targeted therapies in non-small cell lung cancer—is there a „golden standard” in diagnostics? Adv. Respir. Med.82, 311–322 (2014).
Thassu, D., Deleers, M. & Pathak, Y. V. Nanoparticulate drug delivery systems. 166, (CRC Press, 2007).
Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H. & Car, H. Nanoparticles as drug delivery systems. Pharmacol. Reports64, 1020–1037 (2012).
Langer, R. Drug delivery and targeting. NATURE-LONDON- 5–10 (1998).
Zeng, L., Qin, C., Wang, W., Chi, W. & Li, W. Absorption and distribution of chitosan in mice after oral administration. Carbohydr. Polym.71, 435–440 (2008).
Yan, C. et al. 5β-Cholanic Acid/Glycol Chitosan Self-Assembled Nanoparticles (5β-CHA/GC-NPs) for Enhancing the Absorption of FDs and Insulin by Rat Intestinal Membranes. AAPS PharmSciTech20, 30 (2019).
Pi, J. et al. A nano-cocrystal strategy to improve the dissolution rate and oral bioavailability of baicalein. Asian J. Pharm. Sci.14, 154–164 (2019).
Nascimento, A. V. et al. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Acta Biomater.47, 71–80 (2017).
Tsai, W., Yu, K., Huang, Y.-C. & Lee, C.- I. EGFR-targeted photodynamic therapy by curcumin-encapsulated chitosan/TPP nanoparticles. Int. J. Nanomedicine13, 903 (2018).
Jin, H. et al. EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy. Nanoscale9, 16365– 16374 (2017).
Yan, J. et al. Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumour activity against prostate cancer. Biomed. Pharmacother.88, 374–383 (2017).
He, H., Markoutsa, E., Zhan, Y., Zhang, J. & Xu, P. Mussel-inspired PLGA/polydopamine core-shell nanoparticle for light induced cancer thermochemotherapy. Acta Biomater.59, 181– 191 (2017).
Clemons, T. D. et al. Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy. Langmuir34, 15343–15349 (2018).
Cui, X. et al. Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Codelivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy. ACS Appl. Mater. Interfaces10, 7821–7831 (2018).
Gill, M. R. et al. 111 In-labelled polymeric nanoparticles incorporating a rutheniumbased radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cells. Nanoscale10, 10596–10608 (2018).
Ndagi, U., Mhlongo, N. & Soliman, M. E. Metal complexes in cancer therapy–an update from drug design perspective. Drug Des. Devel. Ther.11, 599 (2017).
Sharma, H., Mishra, P. K., Talegaonkar, S. & Vaidya, B. Metal nanoparticles: a theranostic nanotool against cancer. Drug Discov. Today20, 1143–1151 (2015).
Yao, C., Rudnitzki, F., Huettmann, G., Zhang, Z. & Rahmanzadeh, R. Important factors for cell-membrane permeabilization by gold nanoparticles activated by nanosecond-laser irradiation. Int. J. Nanomedicine12, 5659 (2017).
Bhattacharjee, T. T. et al. FTIR study of secondary structure changes in Epidermal Growth Factor by gold nanoparticle conjugation. Biochim. Biophys. Acta (BBA)- General Subj.1862, 495–500 (2018).
Ashton, J. R., Gottlin, E. B., Patz Jr, E. F., West, J. L. & Badea, C. T. A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer. PLoS One13, e0206950 (2018).
Cho, S. K. et al. Multifunctional nanoclusters of NaYF4: Yb3+, Er3+ upconversion nanoparticle and gold nanorod for simultaneous imaging and targeted chemotherapy of bladder cancer. Mater. Sci. Eng. C97, 784–792 (2019).
Groysbeck, N. et al. Synthesis and biological evaluation of 2.4 nm thiolate-protected gold nanoparticles conjugated to Cetuximab for targeting glioblastoma cancer cells via the EGFR. Nanotechnology30, 184005 (2019).
Mu, X. et al. EGFR-targeted delivery of DOX-loaded Fe3O4@ polydopamine multifunctional nanocomposites for MRI and antitumour chemo-photothermal therapy. Int. J. Nanomedicine12, 2899 (2017).
Chen, H.-L. et al. Identification of epidermal growth factor receptor-positive glioblastoma using lipid-encapsulated targeted superparamagnetic iron oxide nanoparticles in vitro. J. Nanobiotechnology15, 86 (2017).
Lu, Q. et al. Fe3O4@ Au composite magnetic nanoparticles modified with cetuximab for targeted magneto-photothermal therapy of glioma cells. Int. J. Nanomedicine13, 2491 (2018).
Bai, K.-J., Chuang, K.-J., Ma, C.-M., Chang, T.-Y. & Chuang, H.-C. Human lung adenocarcinoma cells with an EGFR mutation are sensitive to non-autophagic cell death induced by zinc oxide and aluminium-doped zinc oxide nanoparticles. J. Toxicol. Sci.42, 437–444 (2017).
Li, B., Jiang, Z., Xie, D., Wang, Y. & Lao, X. Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment. Int. J. Nanomedicine13, 7289 (2018).
Pi, J. et al. GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/ AKT and Ras/Raf/MEK/ERK pathways. Drug Deliv.24, 1549–1564 (2017).
Huang, J. et al. Highly Uniform Synthesis of Selenium Nanoparticles with EGFR Targeting and Tumour Microenvironment Responsive Ability for Simultaneous Diagnosis and Therapy of Nasopharyngeal Carcinoma. ACS Appl. Mater. Interfaces (2019).
Kim, J. S. et al. Tumour-specific delivery of therapeutic siRNAs by anti-egFr immunonanoparticles. Int. J. Nanomedicine13, 4817 (2018).
Liang, Y. et al. Smart nanoparticles assembled by endogenous molecules for siRNA delivery and cancer therapy via CD44 and EGFR dualtargeting. Nanomedicine Nanotechnology, Biol. Med.15, 208–217 (2019).
Faucon, A. et al. Bioconjugated fluorescent organic nanoparticles targeting EGFRoverexpressing cancer cells. Nanoscale9, 18094–18106 (2017).
Chen, G., Wang, Y., Xie, R. & Gong, S. Tumour-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery. J. Control. Release259, 105– 114 (2017).
Zhang, Z. et al. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumour ability in colorectal cancer treatment. Int. J. Nanomedicine13, 4961 (2018).
Zhai, J. et al. Paclitaxel-loaded selfassembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer. ACS Appl. Mater. Interfaces10, 25174–25185 (2018).
Zhou, J. et al. PLAUR confers resistance to Gefitinib through EGFR/P-AKT/Survivin signaling pathway. Cell. Physiol. Biochem.47, 1909–1924 (2018).
Refbacks
- There are currently no refbacks.
